Akshay Sood to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Akshay Sood has written about Neoplasm Recurrence, Local.
Connection Strength
2.507
-
Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255.
Score: 0.856
-
Sood A, Keeley J, Palma-Zamora I, Arora S, Dalela D, Olson P, Hanna R, Cotter D, Jeong W, Elshaikh M, Rogers CG, Peabody JO, Menon M, Abdollah F. Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data. Urol Oncol. 2020 06; 38(6):599.e1-599.e8.
Score: 0.667
-
Sood A, Zhang LT, Keeley J, Butaney M, Stricker M, Andrews JR, Grauer R, Peabody JO, Rogers CG, Menon M, Abdollah F. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. Prostate Cancer Prostatic Dis. 2024 Mar; 27(1):58-64.
Score: 0.195
-
Jamil ML, Keeley J, Sood A, Dalela D, Arora S, Peabody JO, Trinh QD, Menon M, Rogers CG, Abdollah F. Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort. Eur Urol. 2020 02; 77(2):277-281.
Score: 0.162
-
Sood A, Abdollah F, Cole D, Alanee S. Re: Stenting prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268. J Urol. 2018 04; 199(4):1069-1070.
Score: 0.143
-
Abdollah F, Moschini M, Sood A, Sammon J, Dalela D, Hsu L, Beyer B, Haese A, Graefen M, Gandaglia G, Montorsi F, Briganti A, Menon M. When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database. J Endourol. 2016 Feb; 30(2):201-7.
Score: 0.122
-
Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur Urol. 2015 Sep; 68(3):497-505.
Score: 0.120
-
Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
Score: 0.053
-
Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol. 2023 02; 41(2):108.e11-108.e17.
Score: 0.050
-
Andrews JR, Ahmed ME, Sharma V, Britton C, Stish B, Phillips R, Kendi AT, Joshi VB, Sood A, Tollefson MK, Boorjian SA, Karnes RJ, Kwon ED. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. J Urol. 2022 12; 208(6):1240-1249.
Score: 0.050
-
Corsi NJ, Messing EM, Sood A, Keeley J, Bronkema C, Rakic N, Jamil M, Dalela D, Arora S, Piontkowski AJ, Majdalany SE, Butaney M, Rakic I, Li P, Menon M, Rogers CG, Abdollah F. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis. Clin Genitourin Cancer. 2022 12; 20(6):e498-e505.
Score: 0.049
-
Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open. 2019 12 03; 9(12):e027066.
Score: 0.041